Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada-Reference-Cited by-同舟云学术

Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada

Published:2022-02-23 Issue:1 Volume:26 Page:74-79
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Shayegan Bobby,Wallis Christopher J. D.^ORCID,Hamilton Robert J.,Morgan Scott C.^ORCID,Cagiannos Ilinas,Basappa Naveen S.,Ferrario Cristiano.,Gotto Geoffrey T.,Fernandes Ricardo,Roy Soumyajit,Noonan Krista L.,Niazi Tamim,Hotte Sebastien J.,Saad Fred^ORCID,Hew Huong,Park-Wyllie Laura,Chan Katherine F. Y.^ORCID,Malone Shawn

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

https://www.nature.com/articles/s41391-022-00514-9.pdf

Reference31 articles.

1. Advanced/Metastatic Prostate Cancer: Clinical Practice Guideline GU-010, version 2: Alberta Health Services. 2020. https://www.albertahealthservices.ca/assets/info/hp/cancer/if-hp-cancer-guide-gu010-met-prostate.pdf.

2. Canadian Cancer Statistics Advisory Committee. Canadian Cancer Statistics: Toronto, ON: Canadian Cancer Society; 2019. cancer.ca/Canadian-Cancer-Statistics-2019-EN.

3. Siegel DA, O’Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity—United States, 2001–2017. MMWR Morb Mortal Wkly Rep. 2020;69:1473–80. https://www.cdc.gov/mmwr/volumes/69/wr/mm6941a1.htm#contribAff.

4. So AI, Chi KN, Danielson B, Fleshner NE, Kapoor A, Niazi T, et al. Canadian Urological Association—Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Can Urol Assoc J. 2020;14:17–23.

5. Mosillo C, Iacovelli R, Ciccarese C, Fantinel E, Bimbatti D, Brunelli M, et al. De novo metastatic castration sensitive prostate cancer: state of art and future perspectives. Cancer Treat Rev. 2018;70:67–74.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does Research from Clinical Trials in Metastatic Hormone-sensitive Prostate Cancer Treatment Translate into Access to Treatments for Patients in the “Real World”? A Systematic Review;European Urology Oncology;2024-02

2. Survival Trend in Individuals With De Novo Metastatic Prostate Cancer After the Introduction of Doublet Therapy;JAMA Network Open;2023-10-02

3. Predictive factors for tolerance to taxane based chemotherapy in older adults affected by metastatic prostate cancer (ANCHISES-NCT05471427): A prospective observational trial including patients with metastatic hormone sensitive and castrate resistant prostate cancer treated with taxane chemotherapy;Journal of Geriatric Oncology;2023-01

4. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis;Prostate Cancer and Prostatic Diseases;2022-10-25

5. Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis;European Urology Oncology;2022-10